 Home > Active Ingredient News > Antitumor Therapy > Radiology: Microcalcification and peritumoral edema predict the prognosis of neoadjuvant chemotherapy for Luminal breast cancer

Radiology: Microcalcification and peritumoral edema predict the prognosis of neoadjuvant chemotherapy for Luminal breast cancer

 Last Update: 2022-10-12
 Source: Internet
 Author: User

Tags

tattoo cancer

rectorseal plus 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Unlike triple-negative or human epidermal growth factor receptor 2-positive breast cancers, in hormonal (i.

Clinicopathological factors known to be associated with the prognosis of Luminal breast cancer treated with NAC include: adherence to adjuvant endocrine therapy, clinical staging before NAC (hereinafter referred to as pre-NAC), pathological staging after NAC, nuclear grade, age, lymphatic vasion, polygene expression characteristics, and Ki-67 index

So far, the role of imaging in predicting pCR has been extensively studied, but little

Recently, a study published in the European Journal of Radiology explored the relationship between imaging (MRI, US and molybdenics) and clinicopathological variables in predicting the survival without distant metastasis (DMFS) and total survival (OS) in patients with Luminal breast cancer treated with NAC, providing theoretical support

This retrospective study collected patients with

The development cohort included 318 women (68 distant metastases, 54 deaths) and the validation cohort included 165 women (37 distant metastases, 14 deaths) (the median age of both cohorts was 46 years).

In this study, predictive models that combined imaging and clinicopathological variables showed good resolution

Original source:

Bo Ra Kwon,Sung Ui Shin,Soo-Yeon Kim,et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.